NasdaqGM - Nasdaq Real Time Price USD

Acrivon Therapeutics, Inc. (ACRV)

2.0300

+0.1200

+(6.28%)

At close: April 22 at 4:00:02 PM EDT

2.0200

-0.01

(-0.49%)

After hours: April 22 at 6:33:06 PM EDT

April 2025's Standout Penny Stocks

The U.S. stock market recently experienced a significant rebound, with major indices like the Dow Jones surging over 1,000 points as investors reacted to a flurry of earnings reports and ongoing tariff discussions. In such a volatile market landscape, identifying potential in smaller or newer companies can be particularly rewarding. While "penny stocks" may sound outdated, they still represent opportunities within less-established firms that could offer substantial value when backed by strong...

Simply Wall St. 8 hours ago

ACRV
+6.28%
SMRT

CCCC
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

The heavy selling pressure might have exhausted for Acrivon Therapeutics, Inc. (ACRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 8 days ago

ACRV
+6.28%
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types

GlobeNewswire 15 days ago

ACRV
+6.28%
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 25 days ago

ACRV
+6.28%
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks

Acrivon Therapeutics, Inc. (ACRV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 25 days ago

ACRV
+6.28%
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heavily pretreated aggressive tumors, and who had all progressed on prior anti-PD-1 and chemotherapy, with 35% confirmed overall response rate (cORR), which is >2-fold higher than last prior line of therapy (15%) In the

GlobeNewswire 26 days ago

ACRV
+6.28%
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316 WATERTOWN, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platfor

GlobeNewswire last month

ACRV
+6.28%
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 2 months ago

ACRV
+6.28%
Acrivon Therapeutics announces FDA granted BDD for ACR-368

Acrivon Therapeutics (ACRV) announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment. The designation reflects the FDA’s determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human dise

TipRanks 2 months ago

ACRV
+6.28%
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay

The assay is developed using the Acrivon Predictive Precision Proteomics platform.

Medical Device Network 2 months ago

ACRV
+6.28%
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status

We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to take a look at where Acrivon Therapeutics, Inc. (NASDAQ:ACRV) stands against other AI news and ratings investors are keeping their eye on. How AI Is Shaping Global Power and Innovation Josh […]

Insider Monkey 2 months ago

ACRV
+6.28%
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with endometrial cancer and other tumor types Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient selection (p-value = 0.009) Drug-tailor

GlobeNewswire 2 months ago

ACRV
+6.28%
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b endometrial cancer study presented at ESMO – Endometrial cancer, a tumor type identified by AP3 as particularly sensitive to ACR-368 treatment, represents the first potential approval opportunity for ACR-368, in second line, with options to move into the front-line setting being eval

GlobeNewswire 5 months ago

ACRV
+6.28%
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

AP3-identified clinical biomarkers for ACR-368 led to the development of a response-predictive OncoSignature assay which has shown statistically significant prospective validation and responder enrichment in the ongoing registrational-intent Phase 2b studyACR-2316, a novel WEE1/PKMYT1 inhibitor, was uniquely enabled and optimized by AP3 to deliver superior single agent activity, complete tumor regression and pro-apoptotic tumor cell death through potent activation of CDK1, CDK2, and PLK1Acrivon

GlobeNewswire 6 months ago

ACRV
+6.28%
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company approved a grant of equity awards under its 2023 Induce

GlobeNewswire 6 months ago

ACRV
+6.28%
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

An update from Acrivon Therapeutics, Inc. ( (ACRV) ) is now available. Acrivon Therapeutics has initiated a Phase 1 clinical trial for ACR-2316, a novel cancer treatment targeting WEE1/PKMYT1 using their proprietary AP3 platform, with the first patient already dosed. This drug, designed to cause complete tumor regression, has been rapidly advanced to trials, demonstrating the company’s efficient drug discovery process. The trial aims to evaluate the safety, tolerability, and optimal dosage of AC

TipRanks 6 months ago

ACRV
+6.28%
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was internally discovered and advanced in 15 months from initial lead to Phase 1 trial initiation uniquely enabled by AP3 - ACR-2316 was rationally designed by AP3 to deliver complete tumor regression and pro-apoptotic tumor cell death through potent activation of CDK1, CDK2, and PLK1 - Initial clinical data from the monotherapy Phase 1 dose optimizatio

GlobeNewswire 6 months ago

ACRV
+6.28%
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tu

GlobeNewswire 7 months ago

ACRV
+6.28%
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced the company’s president and chief executive officer, Peter Blume-Jensen

GlobeNewswire 7 months ago

ACRV
+6.28%
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets ACR-368, ACR-2316, and its AP3 platform WATERTOWN, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discove

GlobeNewswire 7 months ago

ACRV
+6.28%

Performance Overview

Return	ACRV	S&P 500 (^GSPC)
YTD	-66.28%	-10.10%
1-Year	-78.65%	+5.53%
3-Year	-84.79%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Acrivon Therapeutics, Inc. (ACRV)

April 2025's Standout Penny Stocks

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely

Acrivon Therapeutics announces FDA granted BDD for ACR-368

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay

Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

Performance Overview